Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857606 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
A Phase 1 study of Non-alcoholic Fatty Liver Disease, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 10
- Study locations
NCT04857606 is a Phase 1 study of Non-alcoholic Fatty Liver Disease that has completed, run by Amgen. The registered enrollment target is 47 participants, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (75% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT04857606, a Phase 1 study of Non-alcoholic Fatty Liver Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 609
Study Locations (10)
California
- ProSciento Incorporated - Chula Vista
- Catalina Research Institute - Montclair
- Inland Empire Liver Foundation - Rialto
- Orange County Research Center - Tustin
Texas
- Texas Liver Institute - San Antonio
- Endeavor Clinical Trials - San Antonio
- Pinnacle Clinical Research - San Antonio
Arizona
- The Institute for Liver Health - Arizona Liver Health - Chandler
Florida
- Translational Clinical Research LLC - Aventura
Virginia
- McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2023-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857606
The ClinicalTrials.gov registry entry for NCT04857606 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (75% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04857606 reports 10 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT04857606 about?
NCT04857606 is a clinical study titled "Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease". This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).
What is the current status of trial NCT04857606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2021-05-24. Estimated completion is 2023-07-19.
What conditions does trial NCT04857606 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT04857606?
The interventions under investigation include: Placebo (DRUG), AMG 609 (DRUG).
Who is sponsoring clinical trial NCT04857606?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04857606 being conducted?
This trial has 10 study locations across Arizona, California, Florida, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
COMPLETED · Phase 1
-
Phase I Trial of Silymarin for Chronic Liver Diseases
COMPLETED · Phase 1
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.